INDUSTRY ACADEMIC COOPERATION FOUNDATION; HALLYM UNIVERSITY
发明人:
CHOI, SU YOUNG,최수영,PARK, JIN SEO,박진서,HAN, KYU HYUNG,한규형,UM, WON SIK,음원식,SHIN, MIN JEA,신민재,JO, HYO SANG,조효상,SOHN, EUN JEONG,손은정,SON, O RA,손오라,KIM, DUK SOO,김덕수,KIM, DAE WON,김대원,CHOI, SU YOUNGKR,PARK, JIN SEOKR,HAN, KYU HYUNGKR,UM, WON SIKKR,SHIN, MIN JEAKR,JO, HYO SANGKR,SOHN, EUN JEONGKR,SON, O RAKR,KIM, DUK SOOKR,KIM, DAE WONKR
申请号：
KR1020160082193
公开号：
KR1017645830000B1
申请日:
2016.06.30
申请国别(地区):
KR
年份:
2017
代理人:
摘要：
The present invention aims to provide medicines for treating ischemic stroke having or no side effects and having excellent effects. The present invention relates to a pharmaceutical composition for treating ischemic stroke containing cell permeable TXNL1 fusion protein, wherein the TXNL1 fusion protein penetrated into cells increased a cell survival rate to the hydrogen peroxide toxicity and decreased the intracellular reactive oxygen species level and hydrogen peroxide induced DNA fragmentation. In animal models, TXNL1 fusion protein showed a protective effect against neuronal cell death induced by transient ischemia in a CA1 region of the anterior hippocampus. The results suggest that the TXNL1 fusion protein has a protective effect against apoptosis and has a treating effect for protecting nerve cells from damage of ischemic stroke.과제: 부작용이 적거나 없으며, 효과가 우수한 뇌허혈 치료용 약제를 제공하는 것.해결수단: 본 발명은 세포투과성 TXNL1 융합단백질을 포함하는 뇌허혈 치료용 약학 조성물에 관한 것으로서, 세포 내로 투과된 TXNL1 융합단백질은 과산화수소 독성에 대해 세포생존율을 증가시켰고, 세포 내 활성산소종 수준 및 과산화수소로 유도되는 DNA 단편화를 감소시켰다. 동물모델에서는 전뇌 해마 CA1 부분에 일시적 허혈을 유도했을 때 일어나는 신경세포사멸에 대해 TXNL1 융합단백질이 보호효과를 나타내었다. 이러한 결과들은 TXNL1 융합단백질이 세포사멸에 대해 보호효과가 있으며, 뇌허혈 손상으로부터 신경세포를 보호하는 치료효과가 있음을 말해준다.
